gms | German Medical Science

48th Meeting of the Particle Therapy Co-Operative Group

Particle Therapy Co-Operative Group (PTCOG)

28.09. - 03.10.2009, Heidelberg

Particle Therapy for Bone and Soft Tissue Sarcomas: A Retrospective Study

Meeting Abstract

  • Y. Demizu - Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan
  • M. Murakami - Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan
  • D. Miyawaki - Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Japan
  • M. Mima - Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan
  • K. Terashima - Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan
  • T. Arimura - Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan
  • Y. Niwa - Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan
  • Y. Hishikawa - Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan

PTCOG 48. Meeting of the Particle Therapy Co-Operative Group. Heidelberg, 28.09.-03.10.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. Doc09ptcog052

DOI: 10.3205/09ptcog052, URN: urn:nbn:de:0183-09ptcog0521

Veröffentlicht: 24. September 2009

© 2009 Demizu et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Purpose/Objective(s): Bone and soft tissue sarcomas (BSTSs) have been considered to be radioresistant and the mainstay of the treatment is surgery. Particle therapy using carbon ions or protons has potential to be an alternative of surgery in the treatment of BSTSs because of the ability to deliver high dose to tumors while minimizing the dose to organs at risk (carbon ions and protons) and the higher biological effect compared to photons (carbon ions). The purpose of this study was to analyze the results of particle therapy for BSTSs at Hyogo Ion Beam Medical Center (HIBMC) retrospectively.

Materials/methods: Between January 2005 and August 2007, 25 patients with 27 sites of BSTSs were treated with particle therapy at HIBMC. Tumor sites: 7 in the thorax, 8 in the pelvis, 5 in the spine, and 7 in the extremities. Histological types: 7 chondrosarcomas, 5 malignant fibrous histiocytomas (MFHs), 4 osteosarcomas, 3 liposarcomas, 3 malignant peripheral nerve sheath tumors (MPNSTs), and 5 others. Carbon ion therapy of 70.4 GyE/16 fractions was used for 23 lesions, proton therapy of 70.4 GyE/16 fractions for 2 lesions, and proton therapy of 65 GyE/26 fractions for 2 lesions. Overall and progression-free survivals, and local control were evaluated using the Kaplan-Meier method. Acute and late morbidities were assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. The median follow-up was 24 months (range, 2-47 months).

Results: The 2-year overall survival, progression-free survival, and local control rates were 80%, 55%, 76%, respectively. Four lesions developed local recurrence. Distant metastases occurred in 9 patients (bone, lung, etc.). Grade 3 acute skin reactions were observed in 7 sites. As for late adverse effects, grade 4 dermatitis was observed in 4 sites, grade 4 fracture in 1 site, and grade 3 neuropathy in 2 sites.

Conclusions: Particle therapy for BSTSs showed favorable results. Acute and late morbidities were considered acceptable. More accumulation of patients and longer follow-up would be warranted.